Home › Compound Library › GLP-1 & Metabolic › GLP-1/GIP/Glucagon Triple Agonist
GLP-1 & Metabolic Research Emerging

GLP-1/GIP/Glucagon Triple Agonist

Next-generation triple receptor agonist research class (GLP-1 + GIP + glucagon). Represents the frontier beyond tirzepatide dual agonism. Several candidates in research including LY3305677 and CT-996.

GLP-1GIPglucagontriple agonistweight lossnext-generationfrontier
Half-life
Candidate-dependent; weekly dosing targeted for clinical candidates
SKUs Available
1
Evidence Level
Emerging
Mechanism of Action

Simultaneous activation of GLP-1R (incretin/satiety), GIPR (insulin potentiation), and glucagon receptor (hepatic glucose output, direct lipolysis in adipose tissue). Glucagon component adds direct fat mobilization beyond GLP-1/GIP dual agonism.

Published Research Ranges & Study Context

Studies have administered: Research-phase dosing varies by candidate; weekly subcutaneous in early trials

Important Research Framing These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings

Preclinical: superior weight loss vs dual agonists in obesity models. Human phase 1/2 data emerging 2024–2025 showing potential for 25%+ weight loss. Most advanced candidates entering phase 2 trials.

Emerging Early-stage research — limited human data
Side Effects Observed in Research

Anticipated similar GI class effects; additional glucagon-mediated effects (hyperglycemia at high doses) under study

Available Configurations (SKU Reference)
TRI5
Compounds Studied in Combination

These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.

Want a Complete Research Monograph?

Our AI can generate a 2,000+ word deep-dive on GLP-1/GIP/Glucagon Triple Agonist — including full clinical trial summaries, pharmacokinetics, and research frontiers.

Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.